Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › teplizumab

teplizumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of teplizumab

4 trials tracked of teplizumab: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 489 citations.

4Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 2
  1. Phase 3 The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus Completed · 489 cited
  2. Phase 3 Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab Completed · 231 cited
  3. Phase 2 Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" Completed
  4. Phase 2 A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Tzield (teplizumab) to Delay Onset of Stage 3 Type 1 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Tzield (teplizumab) to Delay Onset of Stage 3 Type 1 Diabetes FDA approves Tzield to delay type 1 diabetes in high-risk patients
The FDA approved Tzield (teplizumab) to delay the onset of Stage 3 type 1 diabetes in patients aged 1 year and older with Stage 2 disease.
The FDA approved Tzield (teplizumab) to delay the onset of stage 3 type 1 diabetes in people aged 1 and older with stage 2 disease.
FDA Apr 24, 2026